Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Rev Epidemiol Sante Publique ; 67(3): 181-187, 2019 May.
Article in French | MEDLINE | ID: mdl-30954324

ABSTRACT

BACKGROUND: Prohibition of tobacco sales to minors is a provision of the World Health Organization Framework Convention on tobacco control. This measure is effective to reduce youth tobacco use, if the legislation adopted is properly implemented and enforced. Through the examples of France and Quebec, the objective of this study is to compare legislative frameworks prohibiting tobacco sales to minors, their enforcement, and possible impact on underage smoking. METHODS: Identification of legislative instruments, reports from public health authorities, and articles addressing the focused question was performed trough Medline and Google. RESULTS: Selling tobacco products to minors under 18 years of age has been banned by the law since 1998 in Quebec and 2009 in France. In 2011, in France for individuals aged 17, compliance with the law was 15%. In 2017 in France, 94% of 17-year-old daily smokers regularly bought their cigarettes in a tobacco store. Law enforcement controls and sanctions are non-existent. In 2013 in Quebec, 23% of underage smoking students usually bought their own cigarettes in a business. The compliance rate with the prohibition law rose from 37% in 2003 to 92.6% in 2017. An approach of underage "mystery shoppers" attempting to purchase tobacco products and dedicated inspectors has been implemented, and progressive sanctions are applied in case of non-compliance. In 2013, 12.2% of Quebec high school students and, in 2017, 34.1% of French 17 year olds reported using tobacco products in the last 30 days. CONCLUSION: Only an improved law enforcement, through the training of tobacco retailer's, inspections and effective deterrent penalties for non-compliance, leads to an effective legislative measure in terms of public health.


Subject(s)
Commerce/legislation & jurisprudence , Law Enforcement , Minors/legislation & jurisprudence , Public Health/legislation & jurisprudence , Smoking Prevention , Tobacco Products/legislation & jurisprudence , Adolescent , Adolescent Behavior , Child , Commerce/statistics & numerical data , France/epidemiology , Humans , Law Enforcement/methods , Legislation, Medical , Minors/statistics & numerical data , Public Policy , Quebec/epidemiology , Smoking/epidemiology , Smoking/legislation & jurisprudence , Smoking Prevention/legislation & jurisprudence , Smoking Prevention/organization & administration , Smoking Prevention/standards , Smoking Prevention/statistics & numerical data , Tobacco Industry/economics , Tobacco Industry/legislation & jurisprudence , Tobacco Products/economics , Tobacco Use Disorder/economics , Tobacco Use Disorder/epidemiology
2.
Rev Mal Respir ; 23(4 Suppl): 13S109-18; quiz 13S158, 13S159, 2006 Sep.
Article in French | MEDLINE | ID: mdl-17057636

ABSTRACT

INTRODUCTION: Around the world, due to its high efficiency in delivering nicotine, cigarette is, by far, the first device used to consume tobacco. But, as far as health is concerned, cigarette is the worst nicotine delivery system and cleaner delivery systems would be welcome. In respect to tobacco smoking, up to now, most doctors have supported the "quit smoking or die" dogma. However, some smokers cannot or do not want to completely give up the consumption of nicotine. BACKGROUND: Indeed, while some smokers can stop smoking and, for some of them, simply switch to a nicotine replacement therapy (NRT), other smokers crave the acute effects associated with the rapid massive surge of nicotine delivered to the brain by tobacco smoke. Currently, this rapid nicotine "high" is mainly experienced by smoking cigarettes, thus explaining the high rate of smoking relapse. VIEWPOINT: Thus, for smokers who cannot totally give up nicotine, it is sound to evaluate the rationale for the use of tobacco products with possible lower toxicity than cigarette smoke. CONCLUSIONS: Unfortunately, this important question triggers off passionate statements, while scientific and experimental observations are still very tenuous. Furthermore, the tobacco companies, by producing new tobacco products and promoting the use of smokeless tobacco such as snus, put a constant pressure on the Public Health community.


Subject(s)
Risk Adjustment , Smoking Prevention , Adolescent , Adult , Brain/drug effects , Delayed-Action Preparations , Female , Health Behavior , Humans , Male , Middle Aged , Nicotine/adverse effects , Nicotine/therapeutic use , Nicotinic Agonists/adverse effects , Nicotinic Agonists/therapeutic use , Recurrence , Risk-Taking , Smoke/adverse effects , Smoking Cessation , Nicotiana/adverse effects , Tobacco Use Disorder/prevention & control , Tobacco, Smokeless/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...